Subjective cognitive decline

disease
On this page

Summary

Subjective cognitive decline (MONDO:0850292) is a disease and 88 clinical trials. Top therapeutic interventions include mecamylamine, ginkgo, and inulin. A subtype of cognitive disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 88

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namesubjective cognitive decline
Mondo IDMONDO:0850292
DOIDDOID:0080831
Is cancer (heuristic)no

Disease family

This is a subtype of cognitive disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disordercognitive disordersubjective cognitive decline

Related subtypes (5): amnestic disorder, dementia, alexia, psychotic disorder, delirium

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 88.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified78
PHASE26
EARLY_PHASE12
PHASE2/PHASE31
PHASE1/PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02913664PHASE2/PHASE3COMPLETEDRisk Reduction for Alzheimer’s Disease
NCT05331144PHASE2RECRUITINGImpact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
NCT06588946PHASE2NOT_YET_RECRUITINGΒ-OHB Supplementation and Brain Health in Older Adults
NCT07130669PHASE1/PHASE2RECRUITINGFACE Phase II (a Stage II Trial)
NCT07236190PHASE2RECRUITINGBiomarker-based Trial of NPC-1 for Alzheimer’s Pathology
NCT02755246PHASE2COMPLETEDPolyamine-enriched Diet in Healthy Older Adults With Subjective Cognitive Decline
NCT03057938PHASE2WITHDRAWNSubjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study
NCT03094546PHASE2COMPLETEDPolyamine-enriched Diet in Elderly Individuals With Subjective Cognitive Decline
NCT06002477EARLY_PHASE1RECRUITINGAttentional Mechanisms in SCD
NCT04756232EARLY_PHASE1COMPLETEDCholinergic Mechanisms of Attention in Aging
NCT03271190Not specifiedACTIVE_NOT_RECRUITINGImpact of a Cognitive Intervention Enriched With Leisure Activities in Persons With Subjective Cognitive Decline
NCT03402919Not specifiedRECRUITINGComprehensive Assessment of Neurodegeneration and Dementia
NCT03772977Not specifiedACTIVE_NOT_RECRUITINGThe Brain Health Champion Study
NCT03851523Not specifiedRECRUITINGLongitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer’s Disease.
NCT05014893Not specifiedRECRUITINGNeural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline
NCT06078748Not specifiedACTIVE_NOT_RECRUITINGThe Lifestyle Exercise and Diet Trial (LEAD) 2.0
NCT06095063Not specifiedRECRUITINGdTMS for Subjective Cognitive Decline
NCT06335836Not specifiedRECRUITINGThe Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
NCT06358404Not specifiedRECRUITINGDeveloping a Peer Support Intervention for Depression in SCD
NCT06403345Not specifiedRECRUITINGA Feasiblity Study of Green Activity Program for People Living With Memory Challenges
NCT06429215Not specifiedRECRUITINGREducing the Risk of COgnitive DEcline ad Dementia in Patients With Subjective Cognitive Decline Through an Immersive Virtual Reality and Telemedicine-based Multi-component Intervention: the SCD-ReCODED Study
NCT06433037Not specifiedACTIVE_NOT_RECRUITINGGut-brain Health Effects of PREbiotics in Older Adults With Suspected COgnitive DEcline
NCT06539403Not specifiedRECRUITINGThinking About Memory: How Confident Are You in Your Memory, and Does it Change With Age?
NCT06542458Not specifiedNOT_YET_RECRUITINGUnder-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog
NCT06561906Not specifiedRECRUITINGEstablish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
NCT06621758Not specifiedNOT_YET_RECRUITINGCommunication Regarding Preclinical Dementia Diagnostic and Diagnostic Disclosure Among Patients with MCI and SCD
NCT06622889Not specifiedENROLLING_BY_INVITATIONThe Effectiveness of Interventions Targeting Self-Perception of Aging in Older Adults with Subjective Cognitive Decline
NCT06632145Not specifiedRECRUITINGCog-Fun Ageing Participation-centered, Health Promotion for Older Adults
NCT06650969Not specifiedRECRUITINGChina Diabetes Cognitive Dysfunction Early Diagnosis and Intervention Study (China-DECODE Study)
NCT06669546Not specifiedRECRUITINGEffects of Real vs. Soundless Acoustic Stimulation During Deep Sleep on Brain Activity, Memory, and Blood Biomarkers in Older Adults (60-85) With Mild Memory Impairment
NCT06701630Not specifiedRECRUITINGItalian Adaptation and Validation of Functional and Behavioural Scales for Subjective Cognitive Decline, Mild Cognitive Impairment and Mild Dementia.
NCT06710652Not specifiedNOT_YET_RECRUITINGEfficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Insomnia with Subjective Cognitive Decline
NCT06711952Not specifiedRECRUITINGGerman Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q)
NCT06758154Not specifiedACTIVE_NOT_RECRUITINGEfficacy and Olfactory Network of Electro-acupuncture for Subjective Cognitive Decline: A Multicenter Randomized Controlled Trial and fMRI Study
NCT06816797Not specifiedRECRUITINGTesting the Cog-Fun Aging Program for Older Adults With Subjective Cognitive Decline
NCT06821828Not specifiedNOT_YET_RECRUITINGThe Efficacy of Modified Olfactory Training for MCI High-Risk Individuals
NCT06889818Not specifiedRECRUITINGKorean Joint Registry for Alzheimer’s Treatment and Diagnostics (JOY-ALZ)
NCT06896825Not specifiedRECRUITINGIncreasing Physical Activity Through Social Support and Stress Resilience
NCT06993207Not specifiedRECRUITINGHOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population
NCT07019402Not specifiedACTIVE_NOT_RECRUITINGInternet-based Mind-Body Training for Brain Health

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
MECAMYLAMINE46
GINKGO41
INULIN41
DEXTRIN31
PHENCYCLIDINE HYDROCHLORIDE-11